DNA methylation in brain development and gliomagenesis

Joseph F Costello1

  • 1The Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, 2340 Sutter, San Francisco, CA 94115, USA. jcostello@cc.ucsf.edu

Insights

Epigenomic alterations, specifically aberrant DNA methylation, play a significant role in tumor development, particularly in low-grade gliomas. Understanding these methylation changes is crucial for identifying new therapeutic targets and improving patient survival.

Area of Science:

  • Neuro-oncology
  • Cancer epigenetics
  • Genomics and epigenomics

Background:

  • Tumorigenesis is traditionally viewed as driven by genomic alterations activating oncogenes and inactivating tumor suppressor genes.
  • Epigenomic alterations, such as promoter methylation causing gene silencing, are increasingly recognized as critical in cancer development.
  • Standard genomic screening often misses these crucial epigenomic changes.

Purpose of the Study:

  • To investigate the prevalence and significance of epigenomic alterations, particularly DNA methylation, in tumorigenesis.
  • To explore the role of methylation in normal brain cell function and its dysfunction in brain tumors.
  • To integrate epigenomic insights with traditional genomic models for a comprehensive understanding of glioma genesis and progression.

Main Methods:

  • Genome-wide methylation analysis in cancer cells.
  • Comparison of methylation patterns in tumor tissues versus normal brain cells.
  • Correlation of methylation status with tumor characteristics, therapeutic response, and patient survival.

Main Results:

  • Aberrant methylation is highly prevalent in tumors, especially in low-grade gliomas where genomic alterations are less common.
  • Methylation abnormalities significantly impact tumor progression and patient survival.
  • Specific methylation patterns are linked to tumor response to therapy.

Conclusions:

  • Our understanding of tumor genomes is incomplete, with many prognostic and therapeutic targets potentially residing in the epigenome.
  • Aberrant DNA methylation is a key driver in glioma development and progression, necessitating its consideration alongside genomic alterations.
  • Further research integrating genomic and epigenomic data is vital for advancing brain tumor diagnosis and treatment.